ALNYLAM PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Other Comprehensive Income (Loss), Net of Tax of -$3.00 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-05-01
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-03-31 was -$3.00M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-12-31 was -$9.69M, a 208.12% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $9.81M, a 106.94% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$7.65M, a 474.22% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$11.14M, a 152.37% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $21.28M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$11.39M, a 209.96% decline from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2021 was $10.36M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$3.00M 10-Q · filed 2025-05-01 | -$12.69M derived: sum of 2 quarters · filed 2025-05-01 | -$2.88M derived: sum of 3 quarters · filed 2025-05-01 | -$10.53M derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | -$9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $119.00K derived: sum of 2 quarters · filed 2025-02-13 | -$7.53M derived: sum of 3 quarters · filed 2025-02-13 | -$11.14M 10-K · filed 2025-02-13 |
| 2024-09-30 | $9.81M 10-Q · filed 2024-10-31 | $2.16M derived: sum of 2 quarters · filed 2024-10-31 | -$1.45M 10-Q · filed 2024-10-31 | $7.51M derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-06-30 | -$7.65M 10-Q · filed 2024-10-31 | -$11.26M 10-Q · filed 2024-08-01 | -$2.30M derived: sum of 3 quarters · filed 2025-05-01 | $2.44M derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-03-31 | -$3.61M 10-Q · filed 2025-05-01 | $5.35M derived: sum of 2 quarters · filed 2025-05-01 | $10.09M derived: sum of 3 quarters · filed 2025-05-01 | $12.14M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $13.71M derived: sum of 2 quarters · filed 2025-02-13 | $15.75M derived: sum of 3 quarters · filed 2025-02-13 | $21.28M 10-K · filed 2025-02-13 |
| 2023-09-30 | $4.74M 10-Q · filed 2024-10-31 | $6.79M derived: sum of 2 quarters · filed 2024-10-31 | $12.31M 10-Q · filed 2024-10-31 | $11.44M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $2.04M 10-Q · filed 2024-10-31 | $7.57M 10-Q · filed 2024-08-01 | $6.70M derived: sum of 3 quarters · filed 2025-02-13 | $5.14M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $5.53M 10-Q · filed 2024-10-31 | $4.66M derived: sum of 2 quarters · filed 2025-02-13 | $3.10M derived: sum of 3 quarters · filed 2025-02-13 | -$1.06M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | -$871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$2.43M derived: sum of 2 quarters · filed 2025-02-13 | -$6.59M derived: sum of 3 quarters · filed 2025-02-13 | -$11.39M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$1.56M 10-Q · filed 2023-11-02 | -$5.72M derived: sum of 2 quarters · filed 2023-11-02 | -$10.52M 10-Q · filed 2023-11-02 | -$9.55M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$4.16M 10-Q · filed 2023-11-02 | -$8.96M 10-Q · filed 2023-08-03 | -$7.99M derived: sum of 3 quarters · filed 2024-02-15 | -$6.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$4.81M 10-Q · filed 2023-11-02 | -$3.83M derived: sum of 2 quarters · filed 2024-02-15 | -$1.98M derived: sum of 3 quarters · filed 2024-02-15 | -$1.35M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $971.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $2.82M derived: sum of 2 quarters · filed 2024-02-15 | $3.46M derived: sum of 3 quarters · filed 2024-02-15 | $10.36M 10-K · filed 2024-02-15 |
| 2021-09-30 | $1.85M 10-Q · filed 2022-10-27 | $2.49M derived: sum of 2 quarters · filed 2022-10-27 | $9.39M 10-Q · filed 2022-10-27 | $2.96M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $636.00K 10-Q · filed 2022-10-27 | $7.54M 10-Q · filed 2022-07-28 | $1.11M derived: sum of 3 quarters · filed 2023-02-23 | -$2.87M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $6.91M 10-Q · filed 2022-10-27 | $476.00K derived: sum of 2 quarters · filed 2023-02-23 | -$3.50M derived: sum of 3 quarters · filed 2023-02-23 | -$4.66M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$10.41M derived: sum of 2 quarters · filed 2023-02-23 | -$11.56M derived: sum of 3 quarters · filed 2023-02-23 | -$7.10M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$3.98M 10-Q · filed 2021-10-28 | -$5.13M derived: sum of 2 quarters · filed 2021-10-28 | -$675.00K 10-Q · filed 2021-10-28 | -$2.82M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | -$1.15M 10-Q · filed 2021-10-28 | $3.31M 10-Q · filed 2021-08-03 | $1.16M derived: sum of 3 quarters · filed 2022-02-10 | $2.62M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $4.46M 10-Q · filed 2021-10-28 | $2.31M derived: sum of 2 quarters · filed 2022-02-10 | $3.77M derived: sum of 3 quarters · filed 2022-02-10 | $794.00K derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$687.00K derived: sum of 2 quarters · filed 2022-02-10 | -$3.67M derived: sum of 3 quarters · filed 2022-02-10 | -$3.31M 10-K · filed 2022-02-10 |
| 2019-09-30 | $1.46M 10-Q · filed 2020-11-05 | -$1.52M derived: sum of 2 quarters · filed 2020-11-05 | -$1.16M 10-Q · filed 2020-11-05 | -$979.00K derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$2.98M 10-Q · filed 2020-11-05 | -$2.62M 10-Q · filed 2020-08-06 | -$2.44M derived: sum of 3 quarters · filed 2021-02-11 | -$2.02M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $360.00K 10-Q · filed 2020-11-05 | $539.00K derived: sum of 2 quarters · filed 2021-02-11 | $954.00K derived: sum of 3 quarters · filed 2021-02-11 | $2.00M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $594.00K derived: sum of 2 quarters · filed 2021-02-11 | $1.64M derived: sum of 3 quarters · filed 2021-02-11 | $1.22M 10-K · filed 2021-02-11 |
| 2018-09-30 | $415.00K 10-Q · filed 2019-10-31 | $1.46M derived: sum of 2 quarters · filed 2019-10-31 | $1.04M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $1.05M 10-Q · filed 2019-10-31 | $626.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$420.00K 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | -$992.00K 10-K · filed 2020-02-13 | |||
| 2016-12-31 | -$37.81M 10-K · filed 2019-02-14 | |||
| 2015-12-31 | -$44.39M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |